T-helper 17 lymphocytes in ocular cicatricial pemphigoid

Alessandro Lambiase,1 Alessandra Micera,2 Flavio Mantelli,1 Caterina Moretti,1 Antonio Di Zazzo,1 Eleonora Perrella,3 Sergio Bonini,1 Stefano Bonini1

1Interdisciplinary Center for Biomedical Research (CIR), Laboratory of Ophthalmology, University of Rome “Campus Bio-Medico,” Rome, Italy; 2G.B. Bietti Eye Foundation, Rome, Italy; 3Pathology, University of Rome “Campus Bio-Medico,” Rome, Italy; 4Internal Medicine, Second University of Naples, Naples, Italy

Purpose: T-helper 17 lymphocytes (Th17) were identified in the healthy conjunctiva and in patients with ocular cicatricial pemphigoid (OCP), a disease characterized by chronic ocular surface inflammation.

Methods: Conjunctival biopsies and blood samples were obtained from 10 patients with OCP (4 males, 6 females; 57–90 years of age) and 6 age/sex matched healthy subjects. Conjunctival samples were immunostained with anti-human IL17/CD4 antibodies and stained cells were then counted by confocal microscopy in three 60X field images per each sample. Mononuclear cells were isolated from both OCP and healthy blood samples and evaluated for IL17 and CD4 by FACS. IL17, TGF-β, IL4, and IFN-γ levels were determined in plasma of OCP and healthy patients by ELISA.

Results: The presence of Th17 lymphocytes in conjunctival biopsies was significantly (p<0.05) increased in patients with OCP (14.9±12.8 cells per microscopic field) compared to healthy subjects (0.5±0.8 cells per microscopic field). Th17 lymphocytes comprised 72% of CD4+ cells in four stage-III OCP conjunctival samples. No significant difference was observed for IL17 in peripheral blood of OCP versus healthy subjects.

Conclusions: In this study, we report an increased localization of Th17 lymphocytes in OCP conjunctiva, not accompanied by similar findings in peripheral blood. This finding suggests an increased recruitment of Th17 lymphocytes in conjunctiva and/or a dysfunctional local immune response in the chronically inflamed conjunctiva of OCP. Our findings are in line with previously reported evidence demonstrating that Th17 cells play a critical pathogenic role in mucosal autoimmunity.

The family of CD4+ T-cells includes different subtypes of T-helper (Th) lymphocytes characterized by specific cytokine profiles: Th1 cells secrete IFNγ and IL-2; Th2 cells secrete IL-4, IL-5, and IL-13; and Th17 cells secrete IL-17 [1-5]. Recently, Th17 lymphocytes have been characterized as potent inducers of tissue inflammation in several autoimmune diseases, such as inflammatory bowel disease (IBD), psoriasis, multiple sclerosis (MS), lupus erythematosus systemicus, rheumatoid arthritis (RA), and Bechet’s disease, through the activation of a wide range of inflammatory mediators (IL-6 and IL-8), angiogenesis, and the induction of immune cell activation, particularly neutrophils [6-15]. In fact, increased levels of IL-17 have been detected in biopsies of skin from psoriasis patients, of gut from IBD patients, of brain from MS patients, and of the synovium as well as synovial fluid from RA patients [16]. IL-17 was in fact associated with an increase in both activity and severity of these diseases [17,18]. Concordant results have been obtained in mouse models of RA, in which the local release of IL-17 induces massive damage with extensive inflammatory cell migration, bone erosions, and cartilage degradation [19].

These data indicate a pivotal role of Th17 in regulating the mucosal immune response through migration of immune cells to target organs and induction of pro-inflammatory cytokine release, ultimately leading to tissue damage. However, to date the role of Th17 in ocular inflammatory diseases has been studied only in uveitis and scleritis [12, 20-22].

In this study, we investigated the role played by Th17 lymphocytes in ocular cicatrical pemphigoid (OCP), an autoimmune disease characterized by chronic mucosal inflammation with T-cell dysfunction and infiltration of immune cells in the conjunctiva [23-25].

METHODS

Patients and biological sample handling: The study was performed in accordance to the tenets of the Declaration of Helsinki for research involving human subjects and the Intramural Ethics Committee approved the project. Informed consent was signed by each participant.

Biopsies from temporal bulbar conjunctiva and peripheral blood samples were obtained from 10 patients with OCP (4 males, 6 females; 57–90 years of age) and 6 age/sex matched healthy subjects with no history of dry eye or other ocular diseases at the time of cataract surgery. Healthy subjects were carefully screened for dry eye by rose bengal/fluorescein staining and lacrimal functional tests including tear osmolarity, Schirmer tests, and Tear Film Break-up time test. Table 1 shows the main clinical characteristics of the OCP...
patients recruited for this study at the time of the first visit to our Cornea and External Eye Disease Unit (Campus Bio-Medico University of Rome, Italy). The diagnosis of OCP was based on history, clinical diagnosis, and specific linear direct immunofluorescent labeling of conjunctival basal membrane (Figure 1) [26]. The stage of disease was defined according to the Foster-Mondino classification [27,28]: eight OCP patients recruited for this study were in stage III, one patient was in stage II and one in stage I (Table 1).

Each conjunctival biopsy was 10% formalin fixed and processed for light (histology) or confocal microscopy (immunofluorescence). Blood samples (10 ml) were collected in heparinized vacutainer vials and processed for flow cytometry (enriched peripheral blood mononuclear cells) and ELISA (plasma).

All analytical grade reagents and plasticware were purchased from SERVA (Weidelberg, Germany) and NUNC (Roskilde, Denmark), unless specified differently in the text. Light and confocal microscopy: Paraffin-embedded conjunctival biopsies were serially sliced into 5 μm sections, attached to pretreated slides (Biopptica, Milan, Italy) and processed for either basic histology (hematoxylin and eosin; Biopptica) or direct immunofluorescence, according to standardized procedures.

Direct immunofluorescence on conjunctival biopsies was performed to demonstrate OCP conjunctival basal membrane positivity to goat anti-human FITC-conjugated immunoglobulin (AbD Serotec, Oxford, UK). To identify IL-17 and CD4 positive cells, immunofluorescence staining was performed. Endogenous peroxidase signal was quenched by incubation in 3% H2O2 for 5 min and 50 mM NH4Cl for 2 min; antigen was then retrieved by enzymatic pretreatment...
with hyaluronidase (1mg/ml, in sodium acetic acid; ICN, Costa Mesa, CA). A brief blocking/permeabilizing step was performed for 20 min (0.8% BSA, BSA-0.3% Triton X-100 [TX] in 10 mM phosphate-buffered saline, PBS) before addition of the specific PE conjugated antihuman IL-17 antibodies (2 µg/ml; eBioscience, San Diego, CA), PE-Cy5.5-conjugated antihuman CD4 antibodies (2 µg/ml), or irrelevant isotype-matched IgG antibodies (eBioscience), as negative controls for staining specificity, diluted in 0.1% Tween-20-PBS. Sections of human nasal turbinates were used as positive controls for the internal procedure (data not shown) [29]. Antifade/gel (Vector, Burlingame, CA) mounted sections were examined at 60X magnification in oil immersion using an E2000U three-laser confocal microscope equipped with C1 software (Nikon, Tokyo, Japan).

Three optic fields per each section (3 slides per patient) were acquired randomly in a masked fashion by an independent observer and digitalized using Adobe Photoshop 7.0 (Adobe, San Jose, CA) software. Cell counts were performed by two independent observers. Each observer was blinded to the decision of the other observer [30-32].

**Flow cytometry:** Peripheral blood mononuclear cells (PBMNCs) of OCP patients and controls were obtained from heparinized-whole blood samples, following gradient selection (lympholyteTM; Euroclone, Milan, Italy), according to a standardized procedure. Red cells were lysed (RBC Gentra solution; Qiagen, Mila, Italy) and white cells were directly stored in liquid nitrogen for the following experiments. Direct immunostaining was performed with phycoerythrin (PE)-conjugated antihuman IL17A (0.25 µg/106 cells; ebioscience) and PE-Cy5-conjugated antihuman CD4 (both at 0.25 µg/106 cells; ebioscience), according to the manufacturer's instructions. All samples were analyzed through a FACS Calibur flow cytometer (Becton Dickinson, Milan, Italy) equipped with an argon laser emitting at 488 nm and three band-pass detectors. Forward and side scatter signals were collected as linear signals, and all emissions were evaluated on a four-decade logarithmic scale. PE and PE-Cy5.5 signals were measured, respectively at 575 nm and 670 nm. Spectral overlap was minimized by electronic compensation before each series. CellQuest® software (Becton Dickinson) was used to acquire and evaluate 5,000 events with preserved side scatter signals and high membrane.
staining for specific antibodies [33]. Data were expressed as % of positive cells or mean fluorescence intensity, calculated as follows: ΔMFI=(specific MFI-aspecific MFI)/aspecific MFI.

ELISA assay: To evaluate IL-17, TGF-β, IL-4, and IFN-γ in plasma collected from heparinized peripheral blood of OCP patients and controls, we performed a two-site ELISA (sensitivity=0.5 pg/ml) using commercially available kits and following the manufacturer’s instructions (eBioscience). Optical density (OD) was measured at λ450–550 by a microplate ELISA reader (Sunrise; Tecan Systems, Inc., San Jose, CA).

Statistical analysis: All experiments were performed in duplicate and results are expressed as the mean±standard deviation of the mean (SD). Statistical analyses were performed using ANOVA followed by Tukey-Kramer post-hoc calculations. Analyses were performed using the statistical package StatView II for PC (Abacus Concepts Inc., Berkley, CA). A p value less than 0.05 was considered statistically significant.

RESULTS

All ten OCP conjunctival samples (100%) showed the presence of Th17 lymphocytes, as compared to only two of six healthy subjects (33%). Moreover, the number of Th17 lymphocytes was significantly increased in OCP compared to controls (14.9±12.8 versus 0.5±0.8; p<0.05; Figure 2 A-B). Histological analysis showed that the conjunctiva of OCP patients was infiltrated by immune cells comprised for the most part by lymphocytes, plasma cells and leukocytes (Figure 1). Since T-helper lymphocytes play a major role in the pathogenesis of OCP, the conjunctival lymphocyte infiltrate was characterized by immunostaining. CD4+ cells were significantly increased in OCP compared to healthy conjunctiva (14.7±6.3 versus 4.2±2.1, respectively; p<0.05).

Interestingly, as shown in Figure 2 C-E, double-immunofluorescence of four stage-III OCP conjunctival samples revealed that 72% (range 57%–82%) of the CD4+ cells were of the Th17 type.

Since OCP is a systemic autoimmune disease, the presence of Th17 lymphocytes was also investigated in peripheral blood samples together with the circulating cytokine profile. Flow cytometry results showed that circulating T-helper and Th17 lymphocytes in peripheral blood were not changed in patients affected by OCP (Figure 3). The analysis of IL17-specific immunofluorescence also showed no significant difference between OCP patients and healthy subjects (MFI: 14.8±4.5 versus MFI: 17.1±3.2; ΔMIF: 2.3; p>0.05).

These results were confirmed by ELISA data regarding circulating cytokines (Figure 4). No significant differences in plasma IL-17 (518.2±75 pg/ml versus 466.1±92 pg/ml; p>0.05), IL-4 (57.7±8.4 pg/ml versus 56.8±10.8 pg/ml; p>0.05) or TGF-β (747.4±342.6 pg/ml versus 759.7±126.5 pg/ml; p>0.05) were observed between patients with OCP and healthy subjects. Conversely, a significant increase of circulating IFNγ was observed in patients with OCP (792.7±104.5 pg/ml versus 556.7±184 pg/ml; p<0.05).

DISCUSSION

In this study, we demonstrate that Th17 lymphocytes are present in OCP conjunctiva, and are significantly increased...
compared to healthy controls. Moreover, Th17 comprises the primary subtype of immune cells infiltrating the conjunctiva of OCP patients (more than 70% of CD4+ cells in disease stage III). These data are in line with previous results reported in other human autoimmune diseases, in which a local increase of Th17/IL-17 plays a crucial role in mucosal autoimmunity [19]. It is also worth noting that the predominant Th17 CD4+ subtype in our study was found in the long-standing cases of OCP (mean time from onset of disease: 4 years, range 3–9 years), suggesting that CD4+ Th17 mucosal infiltration could be a marker of chronic inflammatory states of the conjunctiva.

Supporting the hypothesis that Th17 lymphocytes may be responsible for a dysfunctional local immune response in the chronically inflamed OCP conjunctiva, several studies have shown that IL-17-producing-Th17 cells play a critical pathogenic role in autoimmunity, promoting organ-specific damage in several autoimmune diseases such as uveitis, Sjögren’s, MS, IBD, RA, etc. [10,34-40]. In addition, the involvement of Th17 in the pathogenesis of OCP confirms previous observations on the anti-inflammatory effects of macrolides in this disease through inhibition of IL-17-induced IL-8 production [41,42].

In our study Th17 cells were also found in the circulation in both OCP and healthy subjects, where they comprise approximately 10% of CD4+ T lymphocytes. The apparent discrepancy that we observed between conjunctival and peripheral Th17 involvement in OCP may be explained by either a specific Th17-driven local response in the conjunctiva, or an increased Th17 homing to the ocular surface. In line with this hypothesis, Kleinschek et al. [43] recently demonstrated that Th17 cells are imprinted for gut homing, and mediate destructive tissue inflammation in IBD. IFNγ stimulation of local Th17 trafficking may also justify the unchanging circulating number of these cells observed in the OCP patients enrolled in our study [44,45]. Our finding of increased circulating IFNγ associated with normal levels of IL17 is in line with previous reports showing that IFNγ antagonizes Th17 cell development, and allows speculating that overexpression of IFNγ in OCP patients could provoke a compensatory mechanism that ameliorates autoimmune tissue damage [46].

The findings of this study suggest a role of Th17 cells in the pathogenesis of OCP. Identification of novel immune targets such as this provide focus to the search for a more effective therapeutic strategy in OCP. Th17 has already been targeted in other autoimmune diseases and preliminary data indicate that inhibition of Th17 might cure IBD in animal models [47].

ACKNOWLEDGMENTS
Supported by Italian Medicines Agency (AIFA) grant FARM6AS8AW.

REFERENCES
1. Steinman L. A brief history of TH17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13:139-45. [PMID: 17290272]
2. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14:1693-711. [PMID: 10898785]
3. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-46. [PMID: 8820272]
4. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25:821-52. [PMID: 17201677]
5. Ghilardi N, Ouyang W. Targeting the development and effector functions of TH17 cells. Semin Immunol 2007; 19:383-93. [PMID: 18083530]
6. Ma HL, Liang S, Li J, Napierata L, Brown T, Benoit S, Senices M, Gill D, Dunussi-Joannopoulos K, Collins M, Nickerson-Nutter C, Fouser LA, Young DA. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008; 118:597-607. [PMID: 18202747]
7. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, Reinhart TA, McAllister F, Edeal J, Gaus K, Husain S, Kreindler JL, Dubin PJ, Pilewski JM, Myerburg MM, Mason CA, Iwakura Y, Kolls JK. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008; 14:275-81. [PMID: 18264110]
8. Stumvoll GH, DiPaolo RJ, Huter EN, Davidson TS, Glass D, Ward JM, Shevach EM. Th1, Th2, and Th17 effector T cell-induced autoimmune gastritis differs in pathological pattern and in susceptibility to suppression by regulatory T cells. J Immunol 2008; 181:1908-16. [PMID: 18641328]
9. Ouyang W, Kolls JK, Zheng Y. The biological functions of TH17 cell effector cytokines in inflammation. Immunity 2008; 28:454-67. [PMID: 18400188]
10. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20:519-25. [PMID: 18698171]
11. Blauvelt A. T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128:1064-7. [PMID: 18408745]
12. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev 2007; 6:169-75. [PMID: 17289553]
13. Afzali B, Lombardi G, Lechler RI, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007; 148:32-46. [PMID: 17328715]
14. Chi W, Zhu X, Yang P, Liu X, Lin X, Zhou H, Huang X, Kijlstra A. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmo Vis Sci 2008; 49:3058-64. [PMID: 18579762]
15. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol 2009; 27:485-517. [PMID: 19132915]
16. Lubberts E, Schwarzenberger P, Huang W, Schurr JR, Peschon JJ, van den Berg WB, Kolls JK. Requirement of IL-17...
receptor signaling in radiation-resistant cells in the joint for full progression of destructive synovitis. J Immunol 2005; 175:3360-8. [PMID: 16116229]

17. Ziolkowska M, Koc A, Luszczynkiewicz G, Ksiepowlska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-17 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000; 164:2832-8. [PMID: 10679127]

18. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009; 11:625-30. [PMID: 19371791]

19. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den WB. Overexpression of IL-17 in the key joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002; 51:102-4. [PMID: 11930902]

20. Lugier D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Smagellone NM, Chan CC, Caspi RR. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205:799-810. [PMID: 18391061]

21. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, Gery I, Lee YS, Egwuagu CE. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007; 13:711-8. [PMID: 17496900]

22. Fang W, Yang P. Vogt-koyanagi-harada syndrome. Curr Eye Res 2008; 33:517-23. [PMID: 1860484]

23. Ahmed M, Zein G, Khawaja F, Foster CS. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23:579-92. [PMID: 15388075]

24. Razzaque MS, Ahmed BS, Foster CS, Ahmed AR. Effects of IL-4 on conjunctival fibroblasts: possible role in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 2003; 44:3417-23. [PMID: 1288290]

25. Eschle-Meniconi ME, Ahmad SR, Foster CS. Mucous membrane pemphigoid: an update. Curr Opin Ophthalmol 2005; 16:303-7. [PMID: 16175044]

26. Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. Histol Histopathol 2001; 16:1203-12. [PMID: 11642740]

27. Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, Fine JD, Foster CS, Ghosestani R, Hashimoto T, Hoang-Xuan T, Kirtis G, Korman NJ, Lightman S, Lozada-Nur F, Marinkovich MP, Mondino BJ, Prost-Squarcioni C, Rogers RS 3rd, Setterfield JF, West DP, Woinarowska F, Woodley DT, Yancey KB, Zillikens D, Zone JJ. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370-9. [PMID: 11902988]

28. Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982; 89:340-53. [PMID: 7048180]

29. Traves SL, Donnelly LE. TH17 cells in airways diseases. Curr Mol Med 2008; 8:416-26. [PMID: 18691069]

30. Micera A, Lambiase A, Stampachiacchiere B, Sgrulletta R, Normando EM, Bonini S, Bonini S. Nerve growth factor has a modulatory role on human primary fibroblast cultures derived from vernal keratoconjunctivitis-affected conjunctiva. Mol Vis 2007; 13:981-7. [PMID: 17653039]

31. Bonini S, Micera A, Iovieno A, Lambiase A. Expression of Toll-like receptors in healthy and allergic conjunctiva. Ophthalmology 2005; 112:1528. [PMID: 16023216]

32. Micera A, Bonini S, Lambiase A, Lapucci G, Bonini S, Rasi G. Conjunctival expression of thymosin-beta4 in vernal keratoconjunctivitis. Mol Vis 2006; 12:1594-600. [PMID: 17200658]

33. Nakae S, Iwakura Y, Suto H, Galli SJ. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007; 81:1258-68. [PMID: 17307864]

34. Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58:2307-17. [PMID: 18685566]

35. Weiner HL. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008; 255:3-11. [PMID: 18317671]

36. Paradowska A, Masliniski W, Grzybowska-Kowalczyk A, Lacki J. The function of interleukin 17 in the pathogenesis of rheumatoid arthritis. Arch Immunol Ther Exp (Warsz) 2007; 55:329-34. [PMID: 18219763]

37. Maloy KJ. The Interleukin-23 / Interleukin-17 axis in intestinal inflammation. J Intern Med 2008; 263:584-90. [PMID: 18497259]

38. Steinman L. A rush to judgment on Th17. J Exp Med 2008; 205:1517-22. [PMID: 18591407]

39. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002; 71:1-8. [PMID: 11781375]

40. Sakai A, Sugawara Y, Kuroishi T, Sasano T, Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjögren’s syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008; 181:2898-906. [PMID: 18684981]

41. Michel JL, Gain P. Topical tacrolimus treatment for ocular cicatricial pemphigoid. Ann Dermatol Venereol 2006; 133:161-4. [PMID: 16508602]

42. Vanaudenaerde BM, Wyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S, Van Raemdonck DE, Verleden GM. Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant 2007; 7:76-82. [PMID: 17061983]

43. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP, Raskin L, Desai B, Faubion WA, de Waal Malefyt R, Pierce RH, McClanahan T, Kastelein RA. Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation. J Exp Med 2009; 206:525-34. [PMID: 19273624]

44. Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: Immunological roles and clinical implications. Int J Biochem Cell Biol 2008; 41:733-5. [PMID: 18725317]

45. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L, Szeliga W, Wang Y, Liu Y, Welling TH, Elder JT,
Zou W. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181:4733-41. [PMID: 18802076]

46. Chen J, Liu X. The role of interferon gamma in regulation of CD4+ T-cells and its clinical implications. Cell Immunol 2009; 254:85-90. [PMID: 18848698]

47. Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132:2359-70. [PMID: 17570211]